{"id":254881,"date":"2013-01-15T03:46:43","date_gmt":"2013-01-15T03:46:43","guid":{"rendered":"http:\/\/www.eugenesis.com\/biorestorative-therapies-announces-participation-in-adipose-tissue-biology-keystone-conference-series\/"},"modified":"2013-01-15T03:46:43","modified_gmt":"2013-01-15T03:46:43","slug":"biorestorative-therapies-announces-participation-in-adipose-tissue-biology-keystone-conference-series","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/biorestorative-therapies-announces-participation-in-adipose-tissue-biology-keystone-conference-series.php","title":{"rendered":"BioRestorative Therapies Announces Participation in Adipose Tissue Biology Keystone Conference Series"},"content":{"rendered":"<p><p>    JUPITER, Fla., Jan. 14, 2013 \/PRNewswire\/    --BioRestorative Therapies, Inc. (\"BRT\" or the    \"Company\") (BRTX),    a life sciences company focused on adult stem cell    (non-embryonic) based cellular therapies for various personal    medical applications, announced todaythat it has been    invited to present at the Adipose Tissue Biology conference of    the Keystone Symposia conference series on January 30, 2013.    The Conference will be held at the Keystone Resort in Keystone,    Colorado from January 27, 2013 to February 1, 2013.  <\/p>\n<p>    BRT Chief Scientist, Francisco Silva, will be presenting the    Company's research on Human Metabolically Active Brown    Adipose Tissue Derived Stem Cells, which will be readily    available to all organizers, speakers, and attendees of the    conference. This research is a result of the scientific work    BRT has been performing pursuant to its ThermoStem Program    which focuses on treatments for metabolic disorders (diabetes,    heart disease, etc.) and obesity and uses brown fat stem cells.  <\/p>\n<p>    The Keystone Symposia on Molecular and Cellular Biology is a    non-profit organization based in Silverthorne, Colorado that    was founded in 1972. Keystone has shown unrelenting and    uninhibited support for the advancement of biomedical and life    sciences worldwide having convened 50-60 conferences per year    across five continents. The goal of this conference is to    engage researchers from diverse fields to take basic    discoveries in adipocyte biology to the next level, including a    deeper understanding of the etiology of type 2 diabetes and    correlated diseases such as cancer, dementia and asthma through    the conferences joint meeting sessions.  <\/p>\n<p>    About BioRestorative Therapies, Inc. BioRestorative    Therapies, Inc. (\"BRT\") develops medical procedures using cell    and tissue protocols, primarily involving adult stem cells    (non-embryonic), and allowing patients to undergo minimally    invasive cellular-based treatments. BRT is developing the    following scientific initiatives: Our brtxDISC Program (Disc    Implanted Stem Cells) offers a non-surgical treatment for    bulging and herniated discs and addresses the gap between    non-invasive and invasive back procedures. Our ThermoStem    Program focuses on treatments for metabolic disorders    (diabetes, heart disease, etc.) and obesity and uses brown fat    stem cells. Initial research indicates that increased amounts    of brown fat in the body may be responsible for additional    caloric burning as well as reduced glucose and lipid levels in    the body. The Company also offers plant stem cell-based facial    creams and products under the Stem Pearls brand at <a href=\"http:\/\/www.stempearls.com\" rel=\"nofollow\">http:\/\/www.stempearls.com<\/a>.  <\/p>\n<p>    This press release contains \"forward-looking statements\" within    the meaning of Section 27A of the Securities Act of 1933, as    amended, and Section 21E of the Securities Exchange Act of    1934, as amended, and such forward-looking statements are made    pursuant to the safe harbor provisions of the Private    Securities Litigation Reform Act of 1995. You are cautioned    that such statements are subject to a multitude of risks and    uncertainties that could cause future circumstances, events or    results to differ materially from those projected in the    forward-looking statements as a result of various factors and    other risks, including those set forth in the Company's Form    10-K filed with the Securities and Exchange Commission. You    should consider these factors in evaluating the forward-looking    statements included herein, and not place undue reliance on    such statements. The forward-looking statements in this release    are made as of the date hereof and the Company undertakes no    obligation to update such statements.  <\/p>\n<p>    Investor Contacts: KCSA Strategic Communications    Philip Carlson \/ Josh Dver    +1 212.896.1233 \/ +1 212.896.1239    <a href=\"mailto:pcarlson@kcsa.com\">pcarlson@kcsa.com<\/a> \/ <a href=\"mailto:jdver@kcsa.com\">jdver@kcsa.com<\/a>  <\/p>\n<\/p>\n<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Go here to read the rest:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/biorestorative-therapies-announces-participation-adipose-162000652.html;_ylt=A2KJjb0Z0fRQpggAt0__wgt.\" title=\"BioRestorative Therapies Announces Participation in Adipose Tissue Biology Keystone Conference Series\">BioRestorative Therapies Announces Participation in Adipose Tissue Biology Keystone Conference Series<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> JUPITER, Fla., Jan. 14, 2013 \/PRNewswire\/ --BioRestorative Therapies, Inc. (\"BRT\" or the \"Company\") (BRTX), a life sciences company focused on adult stem cell (non-embryonic) based cellular therapies for various personal medical applications, announced todaythat it has been invited to present at the Adipose Tissue Biology conference of the Keystone Symposia conference series on January 30, 2013 <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/biorestorative-therapies-announces-participation-in-adipose-tissue-biology-keystone-conference-series.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577690],"tags":[],"class_list":["post-254881","post","type-post","status-publish","format-standard","hentry","category-biology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254881"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=254881"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254881\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=254881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=254881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=254881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}